LKFT Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (LKFT) is confirmed to report earnings on August 10, 2026, after the market close. The consensus earnings estimate is a loss of $6.74 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lakefront Biotherapeutics NV
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Sector
Healthcare
Industry
Biotechnology